Decoding La Crosse Encephalitis: Why This Virus Deserves More Attention
"Despite its neurological risks, La Crosse Virus research lags behind Zika and Chikungunya. Discover why experts are calling for increased vigilance and preventive measures."
La Crosse Encephalitis (LCE), caused by the La Crosse virus (LACV), is a mosquito-borne illness primarily affecting the brain. Belonging to the Bunyaviridae family and transmitted mainly by Aedes triseriatus mosquitoes, LACV is prevalent in Latin America, the Caribbean, and the United States, especially in the Appalachian and Midwestern regions.
Recent years have seen a concerning rise in LCE cases in the southeastern United States. Health experts believe this increase is partly due to the spread of Aedes albopictus, another mosquito species capable of transmitting LACV. Unlike Aedes aegypti, which is not an efficient vector, Aedes albopictus has become a more common carrier in many areas, heightening the risk of infection.
Given these trends, an observational and descriptive study was conducted to analyze the global scientific research on LACV. This bibliometric study examined scientific publications from three major databases—Science Citation Index (SCI), Scopus, and Medline/PubMed—to assess the extent and focus of current research efforts.
A Disease Named After La Crosse
The Minnesota Department of Health reports that the first recorded La Crosse encephalitis case was in the early 1960s in a Houston County resident. The child died in a La Crosse, Wisconsin, hospital, and the disease was subsequently named after that city. The department says the disease primarily affects children and is spread by infected Aedes triseriatus, or eastern tree hole, mosquitoes.
Diagnostic Tests Described
A parent guide on La Crosse encephalitis diagnosis describes antibody blood tests, MRI brain imaging, and EEGs as tools doctors use when evaluating children. It says these tests help detect La Crosse virus and rule out other viral infections. The source does not provide test-accuracy figures or compare the tests’ performance.
Why La Crosse Virus Research Needs a Boost: Comparing It to Other Viral Threats
The study's findings reveal a significant disparity in research attention between LACV and other viral diseases. While viruses like Zika, Mayaro, and Chikungunya have garnered extensive research efforts, LACV remains comparatively understudied. This gap raises concerns, especially considering LACV's potential to cause neurological complications.
- Limited Global Research: Only 32 related records were retrieved in the search across major scientific databases.
- Geographic Concentration: The majority of studies originated from the United States and Brazil.
- Key Institutions and Authors: The Centers for Disease Control and Prevention (CDC) was identified as the institution with the most research output, with DeFoliart recognized as a leading author in the field.
- Database Discrepancies: No articles were recorded in the SciELO, LILACS, and IMBIOMED databases, indicating a lack of research in these Spanish-language resources.
Limits of Case Counts
CDC historic data are reported by county of residence, not by the county or state where exposure occurred. Separately, CDC notes that ArboNET is a passive surveillance system dependent on patients seeking care, clinicians ordering appropriate tests, and cases being reported, so prevalence is likely underestimated. A CDC FAQ says about 80–100 La Crosse disease cases are reported in the United States each year.
Strain-Specific Differences
A study of La Crosse virus reports strain-specific differences. Its summary describes the virus as the leading cause of pediatric viral encephalitis in North America and an important public health pathogen. It notes that historical pathogenesis studies focused on lineage I strains; the provided summary does not specify the differences found among strains.
The Imperative for Increased Research and Prevention
Given the relatively low research output on LACV compared to other viral threats, there is a clear need to foster greater cooperation and research efforts. With increasing global mobility, LACV poses a risk to travelers' health, underscoring the importance of understanding and preventing its spread. Currently, no specific treatment or vaccine exists for LACV, making preventive measures and further research all the more critical.
A Mosquito-Borne Enzootic Cycle
A 2025 article describes La Crosse virus as a mosquito-borne orthobunyavirus and a significant cause of pediatric viral encephalitis in North America. It says the virus was first isolated in 1960 from a fatal encephalitis case in La Crosse, Wisconsin. The article describes an enzootic cycle involving Aedes triseriatus, the eastern treehole mosquito, and small-mammal amplifier hosts such as chipmunks.
Research Involving Children and Families
The La Crosse Encephalitis Study describes the virus as affecting children in Appalachia and identifies the University of North Carolina–Chapel Hill and Western Carolina University as research partners. Its study page says that when doctors or nurses suspect La Crosse virus infection, they notify the research team. A team member meets with the child’s parent or guardian in the hospital, reviews the study, and asks permission to enroll the child—a process the source calls consent.